FINANCIAL EXPRESS

YES BANK LIMITED

Registered Office: Yes Bank House, Western Express Highway, Santacruz (E), Mumbai, 400 055.

POSSESSION NOTICE (U/s. Rule 8 (1) - for immovable property) The undersigned being the Authorized Officer of YES Bank Ltd. under the provisions of the Securitisation and Reconstruction of Financials Assets and Enforcement of Security Interest Act, 2002 and in exercise of powers conferred under Sec. 13(12) read with rule 9 of the Security Interest (Enforcement) Rules, 2002 issued demand notice calling upon the respective borrowers, co-borrowers, mortgagers & guarantors mentioned hereunder to repay the amounts mentioned in the notices U/s.13(2) of the said Act within a period of 60 days.

The borrowers having failed to repay the said amount, notice is hereby given to the borrowers and public in general that the undersigned has taken symbolic possession of the properties described herein below in exercise of powers conferred on me under Sec. 14/13(4) of the said Act read with Rule 9 of the said Rules.

The respective borrowers in particular and public in general are hereby cautioned not to deal with the said properties and any dealing with this property will be subject to the charge of the YES Bank Ltd. for the respective amount mentioned herein below along with interest thereon at contracted rate.

Name of Borrower and Co-borrowers Guarantors	Loan A/c. No. / Cust ID	Description of Secured Asset	Date of Notice U/s.13(2) Date of Possession	Notice Amount (Rs.)	
and Co-borrowers Guarantors K. R. Steel Coprporation (Propriter: Kirit Chhabildas Sheth), Pankaj C. Sheth, Mrs. Arti Pankaj Sheth, Kirit Chhabildas Sheth Mr.Anil Bhim Singh,	4305267	Secured Property 1:- Office No. 312, 3rd Floor, Dattani Trade Centre Premises CHSL, Chandavarkar Road, Near Municipal Office, Shanti Nagar, Borivali West Mumbai – 400092. Secured Property 2:- AA/9, Ground Floor, 'AA' Wing, Beas Sadan, S No 131 (New) 94 (Old) Village Achole, Near Jaya Hotel, Nallasopara East, Taluka Vasai, Dist. Palghar-401209	14-11-2022	Rs. 1,82,28,706.36/	
		Secured Property 3:- Flat No. 304, 3rd Floor, Bhupati Bldg., Plot No.19, Sector No. 16, Kalamboli, Navi Mumbai - 410218			
Mr.Anil Bhim Singh, Mr. Chhaya Bhimsingh Singh, Mrs. Laxmi A Singh	AFH 000100 466285	Flat No E- 507, Admeasuring 17.920 Sq. Mtr. Carpet Area Along With C.B. Area 1.012 Sq. Mtr., Balcony Area 2.844 Sq. Mtr. & Terrace Area 4.579 Sq. Mtr. on the 5th Floor, Laxmi Castello Situated at Survey No. 63/1, 63/3, 63/4, 63/5, Building E, Bopele, Neral, Taluka Karjat, Dist	28-10-2022 07-02-2023	Rs. 10,76,962.55/-	

As contemplated U/s.13(8) of the Act, in case our dues together with all costs, charges and expenses incurred by us are tendered at any time before the date fixed for sale or transfer, the secured asset shall not be sold or transferred by us, and no further step shall be taken by us for transfer or sale of that secured asset Date: 13-02-2023 Sd/- Authorized Officer

Raigad-410101.

Place: Mumbai YES Bank Ltd. TITAGARH WAGONS LIMITED
CIN: L27320WB1997PLC084819

Registered Office: 756, Anandapur, E M Bypass, Kolkata - 700107 Tel: (033) 40190800. Fax: (033) 40190823, E-mail: corp@titagarh.in, Website: www.titagarh.in

		STANDALONE							CONSOLIDATED							
Particulars		Quarter Ended			Nine Months Ended		Year Ended	Quarter Ended			Nine Months Ended		Year Ended			
	T discussion	December 31, 2022	September 30, 2022	31, 2021	December 31, 2022 (Unaudited)	December 31, 2021 (Unaudited)	March 31, 2022 (Audited)	December 31, 2022 (Unaudited)	September 30, 2022 (Unaudited)	December 31, 2021	December 31, 2022 (Unaudited)	December 31, 2021	March 31, 2022			
		(Unaudited)	(Unaudited)							(Unaudited)		(Unaudited)	(Audited)			
1	Total Income from operations	76,640.28	60,620.45	38,569.71	1,80,631.35	1,07,336.95	1,49,551.20	76,640.28	60,711.53	37,945.16	1,80,537.49	1,04,531.49	1,46,750.42			
2	Net Profit/(Loss) for the period before tax (before Tax and Exceptional items)	5,464.89	4,609.51	2,579.99	12,987.61	8,318.86	11,076,34	4,797.29	4,440.86	2,296.58	12,064.25	7,814.32	10,678.98			
3	Net Profit/(Loss) for the period before tax (after Exceptional items)	5,464.89	-18.04	2,579.99	8,360.06	4,969.50	6,273.88	4,797.29	4,440.86	2,296.58	12,064.25	7,814.32	10,678.98			
4	Net Profit/(Loss) for the period after tax (after Exceptional items)	3,922.88	-1,188.64	1,851.87	5,035.90	2,689.41	3,348.77	3,255.24	4,499.21	147.12	7,747.99	2,462.02	-68.55			
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	3,668.18	-1,899.26	2,061.03	3,919.45	3,086.55	3,919.36	3,136.12	3,864.64	319.69	6,776.01	2,835.17	503.93			
6	Paid-up Equity Share Capital	2,391.42	2,391.42	2,391.42	2,391.42	2,391.42	2,391.42	2,391.42	2,391.42	2,391.42	2,391.42	2,390.34	2,391.42			
7	Other Equity	,52			165	90	84,584.29		00	(0)	53	52	81,821.40			
8	Earnings Per Share (EPS) (Face value of Rs.2 each) (for continuing and discontinued operations)						201									
	Basic (*not annualised)	3.28	-0.99	1.55	4.21	2.25	2.80	2.72	4.03	0.12	6.86	2.06	-0.03			
	Diluted (*not annualised)	3.28	-0.99	1.55	4.21	2.25	2.80	2.72	4.03	0.12	6.86	2.06	-0.03			

Notes:

Place: Kolkata

Date: February 11, 2023

1 The above is an extract of the detailed format of Financial Results for the quarter and nine months ended December 31, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarter and nine months ended December 31, 2022 are available on stock exchanges websites (www.nseindia.com and www.bseindia.com) and on the Company's website (www.titagarh.in)

2 The above financial results for the quarter and nine months ended December 31, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 11th 2023 For and on behalf of Board of Directors

Unesh Chowdhary Vice Chairman & Managing Director

glenmark

GLENMARK PHARMACEUTICALS LIMITED Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099.

Tel No.: +91-22-4018 9999 Fax No.: +91-22-4018 9986

Email: complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com **CIN:** L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2022

Standalone

(All amounts in million of Indian Rupees, unless otherwise stated)

Consolidated

			Quarter ended	Quarter ended	Quarter ended	Nine months	Nine months	Year ended	Quarter ended	Quarter ended	Quarter ended	Nine months	Nine months	Year ended
		Particulars				ended	ended					ended	ended	
			31/12/2022	30/09/2022	31/12/2021	31/12/2022	31/12/2021	31/03/2022	31/12/2022	30/09/2022	31/12/2021	31/12/2022	31/12/2021	31/03/2022
			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	1	Revenue from operations												
		(a) Net sales	21,189.94	21,534.68	20,073.59	61,447.01	62,964.93	80,173.80	33,922.37	33,124.86	31,414.72	94,248.20	92,130.46	121,741.98
		(b) Other operating income	424.77	547.44	256.95	1,369.13	595.44	1,242.01	716.21	627.63	319.42	1,915.75	727.10	1,307.05
		Total revenue from operations	21,614.71	22,082.12	20,330.54	62,816.14	63,560.37	81,415.81	34,638.58	33,752.49	31,734.14	96,163.95	92,857.56	123,049.03
	Ш	Other income	897.28	3,167.28	2,167.43	7,529.74	4,356.47	6,146.28	764.15	974.28	138.95	3,569.99	594.72	1,666.74
	Ш	Total income (I + II)	22,511.99	25,249.40	22,497.97	70,345.88	67,916.84	87,562.09	35,402.73	34,726.77	31,873.09	99,733.94	93,452.28	124,715.77
	IV	Expenses												
		(a) Cost of materials consumed	7,117.03	8,302.43	6,426.96	22,587.88	23,030.61	29,930.36	8,741.85	9,720.06	7,202.05	27,169.95	24,888.23	32,787.57
		(b) Purchases of stock-in-trade	1,097.66	1,013.19	1,255.58	3,051.39	3,838.10	4,816.20	4,543.08	3,317.10	2,744.00	10,378.66	8,792.64	11,176.65
		(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	361.75	(310.25)	49.98	(249.31)	46.72	(161.32)	(1,624.25)	(1,369.87)	772.89	(4,100.17)	(136.70)	(111.37)
		(d) Employee benefits expense	3,571.65	3,809.27	2,943.66	10,403.89	9,076.72	11,931.96	7,559.96	7,310.13	5,859.91	21,233.77	18,697.39	24,474.18
		(e) Finance costs	557.24	524.69	497.72	1,479.56	1,620.31	2,360.41	972.66	830.72	666.95	2,403.27	2,112.44	2980.99
		(f) Depreciation, amortisation and impairment expense	462.20	461.66	407.98	1,374.19	1,179.22	1,596.95	1,622.75	1,557.06	1,189.30	4,647.36	3,551.92	4,867.15
		(g) Other expenses	5,078.23	5,443.18	4,549.54	14,471.36	12,301.86	18,016.40	9,215.50	8,559.46	8,223.77	24,747.71	22,047.01	31,519.01
		Total expenses (IV)	18,245.76	19,244.17	16,131.42	53,118.96	51,093.54	68,490.96	31,031.55	29,924.66	26,658.87	86,480.55	79,952.93	107,694.18
	V	Profit/(loss) before exceptional items and tax (III - IV)	4,266.23	6,005.23	6,366.55	17,226.92	16,823.30	19,071.13	4,371.18	4,802.11	5,214.22	13,253.39	13,499.35	17,021.59
	VI	Exceptional items loss/(gain) (Refer note 5)	(1,625.04)	-	-	(1,625.04)	(4,303.33)	(4,303.33)	(338.78)	-	1,783.80	(338.78)	1,783.80	2,609.13
	VII	Profit/(loss) before tax (V - VI)	5,891.27	6,005.23	6,366.55	18,851.96	21,126.63	23,374.46	4,709.96	4,802.11	3,430.42	13,592.17	11,715.55	14,412.46
	VIII	Tax expense :												
		Current tax	1,035.37	883.83	1,406.48	3,022.77	3,708.13	4,110.78	1,495.82	1,149.49	1,631.30	3,997.68	4,309.30	5466.49
		Deferred tax	550.87	889.89	(525.12)	2,366.84	(503.44)	(714.21)	306.52	865.93	(598.39)	1,789.13	(804.58)	990.52
	IX	Profit/(loss) for the period (VII - VIII)	4,305.03	4,231.51	5,485.19	13,462.35	17,921.94	19,977.89	2,907.62	2,786.69	2,397.51	7,805.36	8,210.83	9,936.49
		Profit/(loss) for the period attributable to:												
		- Non-controlling interests	-	-	-	-	-	-	181.83	182.29	178.49	549.89	349.57	519.38
		- Owners of the Company	4,305.03	4,231.51	5,485.19	13,462.35	17,921.94	19,977.89	2,725.79	2,604.40	2,219.02	7,255.47	7,861.26	9,417.11
	Х	Other comprehensive income												
		A (i) Items that will not be reclassified to profit or loss	1.48	(41.50)	11.59	51.35	15.76	30.53	0.37	(49.09)	17.28	51.07	(24.49)	315.02
		(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.52)	(6.36)	(4.77)	(17.94)	(5.50)	(14.48)	0.24	(4.10)	(4.99)	(15.02)	1.65	(48.53)
		B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	49.81	(560.17)	82.22	1,405.63	525.78	500.62
		(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	(80.24)	(185.64)	(10.88)	(486.20)	(72.76)	-
	ΧI	Total comprehensive income for the period/ year	4,305.99	4,183.65	5,492.01	13,495.76	17,932.20	19,993.94	2,877.80	1,987.69	2,481.14	8,760.84	8,641.01	10,703.60
	XII	Total comprehensive income attributable to:												
		- Non-controlling interests	-	-	-	-	_	-	180.99	181.66	178.52	548.53	349.73	519.97
		- Owners of the Company	4,305.99	4,183.65	5,492.01	13,495.76	17,932.20	19,993.94	2,696.81	1,806.03	2,302.62	8,212.31	8,291.28	10,183.63
	XIII	Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17
	XIV	Other equity						167,103.70						90,584.30
	XV	Earning per share (EPS)												
		(of Re 1/- each) (not annualised)*												
		Basic EPS (in Rupees)	15.26	15.00	19.44	47.71	63.52	70.80	9.66	9.23	7.86	25.71	27.86	33.37
		Diluted EPS (in Rupees)	15.26	15.00	19.44	47.71	63.52	70.80	9.66			25.71	27.86	33.37
*		ot for the year ended 31 March												

* except for the year ended 31 March

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- The above results were reviewed by the Audit Committee at its meeting held on 9 February, 2023 and approved by the Board of Directors at its meeting held on 10 February, 2023. The results for the quarter and nine months ended 31 December, 2022 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e., Pharmaceuticals.
- As at 31 December, 2022, pursuant to Employee Stock Options Scheme 2016, 78,717 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. Exceptional item: 31 December, 2022
- The exceptional item in consolidated result is net gain of Rs 338.78 arising from the sale cardiac brand Razel (India and Nepal business), net of expenses and remediation cost of Monroe manufacturing site (USA) The exceptional item in standalone result is net gain of Rs 1,625.04 arising from the sale cardiac brand Razel (India and Nepal business), net of expenses, trade receivables, inventory write off and other reimbursable expenses. 31 December, 2021:
- Exceptional item of Rs. 1,783.80 in consolidated result for the quarter and nine months ended 31 December, 2021 comprises of impairment of certain intangible assets. On 3 August, 2021, Glenmark Life Sciences Limited (GLS) completed allotment of shares as part of its Initial Public Offering (IPO) and Offer for Sale (OFS). The company offered 6.3 million equity shares of Rs 2 each through OFS and resulted in a gain of Rs 4,303.33 (net of related expenses and cost of equity shares)
- and recorded as an exceptional item in the standalone financial results. Pursuant to requirements of Ind AS 110 para 23 and B96 such gain and tax thereon is directly recognised in equity in consolidated financial statements. The list of subsidiaries as of 31 December, 2022 is provided in Annexure A.
- The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and nine months ended 31 December, 2022.
- Diluted EPS has been computed considering the effect of conversion of ESOPs. 9 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.
- Annexure A List of entities included in the consolidated financial results for the quarter and nine months ended 31 December 2022

1 Glenmark Pharmaceuticals Europe Ltd., U.K. 2 Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. (liquidated with effect from 4 January 2022) 3 Glenmark Pharmaceuticals SK, S.R.O. 5 Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 6 Glenmark Holding S.A. 7 Glenmark Pharmaceuticals SP z.o.o. 8 Glenmark Pharmaceuticals Inc. 9 Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 13 Glenmark Pharmaceuticals Peru SAC 14 Glenmark Pharmaceuticals Colombia SAS, Colombia 15 Glenmark Uruguay S.A. 16 Glenmark Pharmaceuticals Venezuela, C.A 17 Glenmark Pharmaceuticals FZE 20 Glenmark Pharmaceuticals Egypt S.A.E. 19 Glenmark Pharmaceuticals (Nigeria) Ltd 23 Glenmark Pharmaceuticals Malaysia Sdn Bhd 24 Glenmark Pharmaceuticals (Australia) Pty Ltd 25 Glenmark Pharmaceuticals (Thailand) Co. Ltd 28 Glenmark Pharmaceuticals B.V. 29 Glenmark Pharmaceuticals Gmbh 30 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals B.V. 29 Glenmark Pharmaceuticals Gmbh 30 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Gmbh 30 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals B.V. 29 Glenmark Pharmaceuticals Gmbh 30 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 33 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 33 Glenmark Pharmaceuticals Canada Inc. 34 Glenmark Pharmaceuticals Canada Inc. 34 Glenmark Pharmaceuticals Canada Inc. 35 Glenmark Pharmaceuticals Canada Inc. 36 Glenmark Pharmaceuticals Cana Pharmaceuticals Kenya Ltd 32 Viso Farmaceutica S.L., Spain 33 Glenmark Pharmaceuticals Distribution s.r.o. 35 Glenmark Pharmaceuticals Ecuador S.A. 38 Glenmark Pharmaceuticals Singapore Pte. Ltd. 39 Ichnos Sciences Biotherapeutics SA 40 Ichnos Sciences Inc., USA 41 Glenmark Life Sciences Limited

For and on behalf of the Board of Directors

Mumbai, 10 February, 2023

Glenn Saldanha **Chairman & Managing Director**

CORRIGENDUM: The quarterly financial results advertisement published in Financial Express, Mumbai edition on Sunday, February 12, 2023 was wrongly published by the advertising agency. The correct quarterly results had already been uploaded on the BSE, NSE and company websites. Kindly ignore the advertisement published on Sunday, February 12, 2023. The above advertisement contains the advertisement which had been approved by the Company for publication i.e. financial results for the quarter and nine months ended December 31, 2022.











अर्थसंकल्प आणि त्याने दिलेल्या धोरण दिशेचा अन्वयार्थ

पनवेलमध्ये श्रुक्रवारी यंदाच्या अर्थसंकल्पातील तरतुदींचे विश्लेषण

लोकसत्ता प्रतिनिधी

मुंबई: अर्थमंत्री निर्मला सीतारामन यांनी त्यांच्या कारकीर्दीतील पाचवा अर्थसंकल्प महिन्याच्या प्रारंभी लोकसभेत मांडला. वित्तीय तूट आटोक्यात ठेवून, विकासाची गती वाढविण्याचा संकल्प सोडणाऱ्या अर्थमंत्र्यांच्या भाषणाचा आणि त्यामागील अर्थाचा उलगडा येत्या शुक्रवारी सायंकाळी पनवेलमध्ये आयोजित 'लोकसत्ता विश्लेषण' या विशेष अर्थसंकल्पोत्तर कार्यक्रमातन केला जाणार आहे.

देशाचा अर्थव्यवस्थेचा भविष्यपट मांडणारा २०२३-२४ सालच्या केंद्रीय अर्थसंकल्पातील तरतुदी आणि घोषणांचा वेध घेणारा हा 'लोकसत्ता विश्लेषण' कार्यक्रम शुक्रवार, १७ फेब्रुवारीला सायंकाळी ६ वाजता, आद्य क्रांतिवीर वासुदेव बळवंत फडके सभागृह, डॉ. बाबासाहेब आंबेडकर रोड, रोटरी गार्डनजवळ, पनवेल या ठिकाणी होत आहे.

'लोकसत्ता'चे संपादक गिरीश कुबेर आणि वरिष्ठ सनदी लेखापाल दीपक टिकेकर हे अर्थमंत्र्यांपुढे असणारी आव्हाने पाहता त्यांनी

■ कधी : शुक्रवार, १७ फेब्रुवारी २०२३ ■ वेळ : सायंकाळी ६.०० वाजता ■ वक्ते : गिरीश कुबेर, संपादक, लोकसत्ता दीपक टिकेकर, कर सल्लागार ■ स्थळ : आद्य क्रांतिवीर वासुदेव बळवंत फडके सभागृह, डॉ. बाबासाहेब आंबेडकर रोड, रोटरी गार्डनजवळ, पनवेल

े होंकसत्ता

साधलेल्या कसरतींचा यानिमित्ताने आढावा घेतील.

पॉवर्ड बाय इ इंडियन ऑइल कॉर्पोरेशन लिमिटेड सह-प्रायोजित हा कार्यक्रम सर्वांसाठी खुला आणि विनामुल्य आहे.

व्यक्तिगत करदात्यांवरील प्राप्तिकराचा भार हलका करणारी नवीन करप्रणाली हे यंदाचे अर्थसंकल्पाचे सामान्यांच्या दृष्टीने

मोठे वैशिष्ट्य सांगितले जात आहे. कोणतीही वजावट न घेता सवलतीच्या दरात कर भरण्याचा पर्याय देणाऱ्या नवीन करप्रणालीचा स्वीकार करावा, असाच अर्थमंत्र्यांचा संदेश आहे. मात्र यातृन करबचतीसाठी गुंतवणूक करण्याची पारंपरिक पद्धत मोडीत काढली जाईल काय? तसे झाल्यास त्याचे काय परिणाम दिसतील? मुळात नवीन अथवा जुनी यापैकी कोणती प्रणाली स्वीकारणे कोणासाठी फायद्याचे ठरेल? अशा प्रश्नांचे सोपे-सुलभ उत्तर या कार्यक्रमातून उपस्थितांना मिळविता येईल.

जागतिक मंदी, रशिया-युक्रेन युद्ध असा आव्हानांचा काळ असूनही भारतीय अर्थव्यवस्था योग्य मार्गावर आहे आणि तिचा वाढीचा दर जगात सर्वात जास्त असल्याचे अर्थमंत्र्यांनी आपल्या भाषणात सांगितले. तथापि वाढती महागाई आणि घटती क्रयशक्ती पाहता, लोकांच्या उत्पन्नाची पातळी वाढेल अशा अपेक्षांची अर्थसंकल्पाकडून कशी आणि कितपत दखल घेतली गेली, अशा प्रत्येक पैलूचा वेध घेणाऱ्या या कार्यक्रमात सर्वांचा सहभाग अगत्याचाच

करोनानंतरही परीक्षार्थींच्या सवलतींसाठी पालक आग्रही

परीक्षेपूर्वी दहा मिनिटे प्रश्नपत्रिका देण्याचा निर्णय मागे घेतल्याने नाराजी

लोकसत्ता प्रतिनिधी

मुंबई: करोना कालावधीनंतर झालेल्या दहावी, बारावीच्या परीक्षांसाठी राज्यमंडळाने अपवाद म्हणून दिलेली वेळेची सवलत आता मागे घेतली आहे. त्याचबरोबर काही वर्षांपासून प्रश्नपत्रिका फुटण्याच्या सातत्याने होणाऱ्या घटनांना आळा परीक्षा घालण्यासाठी होण्यापूर्वी दहा मिनिटे प्रश्नपत्रिका देण्याच्या निर्णयही बदलला असून पालकांनीच या निर्णयाविरोधात सुर

आळवायला सुरुवात केली आहे. गेल्या काही वर्षांपासून प्रत्यक्ष परीक्षा सुरू होण्यापूर्वी दहा मिनिटे विद्यार्थ्यांना प्रश्नपत्रिका देण्यात येत असे. विद्यार्थ्यांनी प्रश्नपत्रिका नीट वाचायला मिळावी असा हेत् असल्याचे सांगून शिवसेना-भाजप युती शासनाच्या काळात हा निर्णय घेण्यात आला होता. मात्र, त्यानंतर परीक्षेच्या वेळेपूर्वीच म्हणजे प्रश्नपत्रिका वाटल्यानंतर तिच्या लिखाणासाठीची वेळ होण्याच्या मधल्या दहा मिनिटांच्या

भाजप शासनाच्या काळातील निर्णय मागे..

विद्यार्थ्यांना परीक्षा सुरू होण्यापूर्वी दहा मिनिटे प्रश्नपत्रिका देण्याचा निर्णय शिवसेना. भाजप शासनाच्या काळात विनोद तावडे हे शिक्षणमंत्री असताना घेण्यात आला होता. राज्यात अनेक राजकीय घडामोडींसह भाजपची शिंदे गटासह सत्ता आहे. असे असताना भाजप शासनाच्याच काळात घेण्यात आलेला निर्णय आता रद्द करण्यात आला आहे.

कालावधीत प्रश्नपत्रिका प्रसारित समाजमाध्यमांवर झाल्याच्या अनेक घटना समोर आल्या. त्या पार्श्वभूमीवर राज्यमंडळाने प्रश्नपत्रिका वेळेपूर्वी वाटण्याचा निर्णय मागे घेतला. त्याचबरोबर करोना कालावधीत प्रश्नपत्रिका सोडवण्यासाठी देण्यात आलेला अतिरिक्त वेळही आता रद्द करण्यात आली आहे.

मंडळाच्या या निर्णयामुळे उत्तरपत्रिका वेळेत लिहन कशी पूर्ण होणार, असे प्रश्न उपस्थित करून पालकांनीच आता या निर्णयावर केली आहे.

भांड्पमध्ये दुमजली दुकान कोसळून दोघांचा मृत्यू

मुंबई: डागडुजीचे काम सुरू असताना दुमजली कोसळल्याची घटना रविवारी सकाळी भांडुप येथे घडली. यामध्ये दोन कामगारांचा मृत्यू झाला.

भांडुपच्या खिडीपाडा परिसरातील क्रांती मित्रमंडळ परिसरात दोन दिवसांपासून एका दुमजली दुकानाच्या डागडुजीचे काम सुरू होते. त्यावेळी दोन कामगार दुकानातच झोपले असताना साडेनऊच्या सुमारास अचानक छत आणि दोन भिंती कोसळल्या. या घटनेनंतर स्थानिकांनी

तत्काळ अग्निशमन दलाशी संपर्क साधला. त्यानंतर घटनास्थळी दाखल झालेल्या अग्निशमन दलाच्या जवानांनी ढिगारा बाजूला करून, राजकुमार सहाय्य (वय २१) आणि रामाअवतार यादव (वय १९) या दोन कामगारांना बाहेर काढले. त्यानंतर दोघांना पालिकेच्या उपचारासाठी अगरवाल रुग्णालयात दाखल करण्यात आले. मात्र उपचारापूर्वीच दोघांचा मृत्यू झाला.

भांडुप पोलिसांनी याप्रकरणी चार जणांवर गुन्हा दाखल केला असून, मारुती शेलार, राजू शेख आणि मोहम्मद रशीद खान या तिघांना अटक आहे.

आयआयटी मुंबईतील १८ वर्षीय विद्यार्थ्याची आत्महत्या

मुंबई: आयआयटी मुंबईमध्ये रासायनिक अभियांत्रिकीचा पदवी अभ्यास करणाऱ्या १८ वर्षीय विद्यार्थ्याने रविवारी वसतिगृहाच्या इमारतीच्या सातव्या मजल्यावरून उडी मारून आत्महत्या केली.

गुजरातमधील दर्शन सोळंकी तीन महिन्यांपूर्वी पवई येथील आयआयटी मुंबईमध्ये दाखल

झाला होता. पहिल्या सत्राची परीक्षा शनिवारी संपली. त्यानंतर दुसऱ्याच दिवशी, त्याने आत्महत्या केली. त्यामुळे शैक्षणिक दबावामुळे त्याने पाऊल उचलल्याची शक्यता वर्तवण्यात आली. अभ्यासाचा तणाव यांमुळे आत्महत्या केली का किंवा अन्य कारण आहे का, याचा तपास सुरू आहे.



glenmark

GLENMARK PHARMACEUTICALS LIMITED

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mahalaxmi, Mumbai - 400 026. Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai - 400 099. Tel No.: +91-22-4018 9999 Fax No.: +91-22-4018 9986

Email: complianceofficer@glenmarkpharma.com **Website:** www.glenmarkpharma.com **CIN:** L24299MH1977PLC019982

Statement of unaudited financial results for the quarter and nine months ended 31 December, 2022

Standalone

(All amounts in million of Indian Rupees, unless otherwise stated)

Consolidated

	Standalone						Consolidated					
Particulars	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended	Quarter ended	Quarter ended	Quarter ended	Nine months ended	Nine months ended	Year ended
	31/12/2022	30/09/2022	31/12/2021	31/12/2022	31/12/2021	31/03/2022	31/12/2022	30/09/2022	31/12/2021	31/12/2022	31/12/2021	31/03/2022
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from operations						1						
(a) Net sales	21,189.94	21,534.68	20,073.59	61,447.01	62,964.93	80,173.80	33,922.37	33,124.86	31,414.72	94,248.20	92,130.46	121,741.98
(b) Other operating income	424.77	547.44	256.95	1,369.13	595.44	1,242.01	716.21	627.63	319.42	1,915.75	727.10	1,307.05
Total revenue from operations	21,614.71	22,082.12	20,330.54	62,816.14	63,560.37	81,415.81	34,638.58	33,752.49	31,734.14	96,163.95	92,857.56	123,049.03
II Other income	897.28	3,167.28	2,167.43	7,529.74	4,356.47	6,146.28	764.15	974.28	138.95	3,569.99	594.72	1,666.74
III Total income (I + II)	22,511.99	25,249.40	22,497.97	70,345.88	67,916.84	87,562.09	35,402.73	34,726.77	31,873.09	99,733.94	93,452.28	124,715.77
IV Expenses												
(a) Cost of materials consumed	7,117.03	8,302.43	6,426.96	22,587.88	23,030.61	29,930.36	8,741.85	9,720.06	7,202.05	27,169.95	24,888.23	32,787.57
(b) Purchases of stock-in-trade	1,097.66	1,013.19	1,255.58	3,051.39	3,838.10	4,816.20	4,543.08	3,317.10	2,744.00	10,378.66	8,792.64	11,176.65
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	361.75	(310.25)	49.98	(249.31)	46.72	(161.32)	(1,624.25)	(1,369.87)	772.89	(4,100.17)	(136.70)	(111.37)
(d) Employee benefits expense	3,571.65	3,809.27	2,943.66	10,403.89	9,076.72	11,931.96	7,559.96	7,310.13	5,859.91	21,233.77	18,697.39	24,474.18
(e) Finance costs	557.24	524.69	497.72	1,479.56	1,620.31	2,360.41	972.66	830.72	666.95	2,403.27	2,112.44	2980.99
(f) Depreciation, amortisation and impairment expense	462.20	461.66	407.98	1,374.19	1,179.22	1,596.95	1,622.75	1,557.06	1,189.30	4,647.36	3,551.92	4,867.15
(g) Other expenses	5,078.23	5,443.18	4,549.54	14,471.36	12,301.86	18,016.40	9,215.50	8,559.46	8,223.77	24,747.71	22,047.01	31,519.01
Total expenses (IV)	18,245.76	19,244.17	16,131.42	53,118.96	51,093.54	68,490.96	31,031.55	29,924.66	26,658.87	86,480.55	79,952.93	107,694.18
V Profit/(loss) before exceptional items and tax (III - IV)	4,266.23	6,005.23	6,366.55	17,226.92	16,823.30	19,071.13	4,371.18	4,802.11	5,214.22	13,253.39	13,499.35	17,021.59
VI Exceptional items loss/(gain) (Refer note 5)	(1,625.04)	-	-	(1,625.04)	(4,303.33)	(4,303.33)	(338.78)	-	1,783.80	(338.78)	1,783.80	2,609.13
VII Profit/(loss) before tax (V - VI)	5,891.27	6,005.23	6,366.55	18,851.96	21,126.63	23,374.46	4,709.96	4,802.11	3,430.42	13,592.17	11,715.55	14,412.46
VIII Tax expense :												
Current tax	1,035.37	883.83	1,406.48	3,022.77	3,708.13	4,110.78	1,495.82	1,149.49	1,631.30	3,997.68	4,309.30	5466.49
Deferred tax	550.87	889.89	(525.12)	2,366.84	(503.44)	(714.21)	306.52	865.93	(598.39)	1,789.13	(804.58)	990.52
IX Profit/(loss) for the period (VII - VIII)	4,305.03	4,231.51	5,485.19	13,462.35	17,921.94	19,977.89	2,907.62	2,786.69	2,397.51	7,805.36	8,210.83	9,936.49
Profit/(loss) for the period attributable to:												
- Non-controlling interests	-	-	-	-	-	-	181.83	182.29	178.49	549.89	349.57	519.38
- Owners of the Company	4,305.03	4,231.51	5,485.19	13,462.35	17,921.94	19,977.89	2,725.79	2,604.40	2,219.02	7,255.47	7,861.26	9,417.11
X Other comprehensive income												
A (i) Items that will not be reclassified to profit or loss	1.48	(41.50)	11.59	51.35	15.76	30.53	0.37	(49.09)	17.28	51.07	(24.49)	315.02
(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.52)	(6.36)	(4.77)	(17.94)	(5.50)	(14.48)	0.24	(4.10)	(4.99)	(15.02)	1.65	(48.53)
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	49.81	(560.17)	82.22	1,405.63	525.78	500.62
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	(80.24)	(185.64)	(10.88)	(486.20)	(72.76)	-
XI Total comprehensive income for the period/ year	4,305.99	4,183.65	5,492.01	13,495.76	17,932.20	19,993.94	2,877.80	1,987.69	2,481.14	8,760.84	8,641.01	10,703.60
XII Total comprehensive income attributable to:												
- Non-controlling interests	-	-	-	-	-	-	180.99	181.66	178.52	548.53	349.73	519.97
- Owners of the Company	4,305.99	4,183.65	5,492.01	13,495.76	17,932.20	19,993.94	2,696.81	1,806.03	2,302.62	8,212.31	8,291.28	10,183.63
XIII Paid up Equity Share Capital, Equity Shares of Re. 1/- each	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17	282.17
XIV Other equity						167,103.70						90,584.30
XV Earning per share (EPS)												
(of Re 1/- each) (not annualised)*												
Basic EPS (in Rupees)	15.26	15.00	19.44	47.71	63.52	70.80	9.66	9.23	7.86	25.71	27.86	33.37
Diluted EPS (in Rupees)	15.26	15.00	19.44	47.71	63.52	70.80	9.66	9.23	7.86	25.71	27.86	33.37
* except for the year ended 31 March	1/0		17/1		,ti	N 02	V08 (c)v.	100			100	

- Notes: 1 The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- The above results were reviewed by the Audit Committee at its meeting held on 9 February, 2023 and approved by the Board of Directors at its meeting held on 10 February, 2023. The results for the quarter and nine months ended 31 December, 2022 presented were subjected to a "Limited Review" by statutory auditors of the Company who have issued an unmodified report on the said results.
- The Chief Operating Decision Maker ("CODM") reviews the financial performance at pharmaceutical business level, comprising of generics and active pharmaceutical ingredient components, which are interlinked and inter-dependent, therefore, the Company has only one reportable segment, i.e.,
- As at 31 December, 2022, pursuant to Employee Stock Options Scheme 2016, 78,717 options were outstanding, which upon exercise are convertible into equivalent number of equity shares. 5 Exceptional item:

31 December, 2022

The exceptional item in consolidated result is net gain of Rs 338.78 arising from the sale cardiac brand Razel (India and Nepal business), net of expenses and remediation cost of Monroe manufacturing site (USA). The exceptional item in standalone result is net gain of Rs 1,625.04 arising from the sale cardiac brand Razel (India and Nepal business), net of expenses, trade receivables, inventory write off and other reimbursable expenses. 31 December, 2021:

Exceptional item of Rs. 1,783.80 in consolidated result for the quarter and nine months ended 31 December, 2021 comprises of impairment of certain intangible assets.

On 3 August, 2021, Glenmark Life Sciences Limited (GLS) completed allotment of shares as part of its Initial Public Offering (IPO) and Offer for Sale (OFS). The company offered 6.3 million equity shares of Rs 2 each through OFS and resulted in a gain of Rs 4,303.33 (net of related expenses and cost of equity shares) and recorded as an exceptional item in the standalone financial results. Pursuant to requirements of Ind AS 110 para 23 and B96 such gain and tax thereon is directly recognised in equity in consolidated financial statements. The list of subsidiaries as of 31 December, 2022 is provided in Annexure A.

The Group continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and how it will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of goodwill, investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the financial results for the quarter and nine months ended 31 December, 2022.

Diluted EPS has been computed considering the effect of conversion of ESOPs. 9 Previous period's figures have been re-grouped/re-classified to render them comparable with the figures of the current period.

List of entities included in the consolidated financial results for the quarter and nine months ended 31 December 2022

1 Glenmark Pharmaceuticals Europe Ltd., U.K. 2 Glenmark Pharmaceuticals S.R.O. 4 Glenmark Pharmaceuticals S.R.O. 5 Ichnos Sciences SA (Formerly known as Glenmark Pharmaceuticals S. A.) 6 Glenmark Holding S.A. 7 Glenmark Pharmaceuticals SP z.o.o. 8 Glenmark Pharmaceuticals Inc. 9 Glenmark Pharmaceuticals Inc. 9 Glenmark Pharmaceuticals Peru SAC 14 Glenmark Pharmaceuticals Peru SAC 14 Glenmark Pharmaceuticals Colombia SAS, Colombia 15 Glenmark Uruguay S.A. 16 Glenmark Pharmaceuticals Venezuela, C.A 17 Glenmark Pharmaceuticals FZE 20 Glenmark Pharmaceutical Sdn Bhd 24 Glenmark Pharmaceuticals (Australia) Pty Ltd 25 Glenmark Pharmaceuticals (Australia) Pty Ltd 25 Glenmark Pharmaceuticals (Denmark Pharmaceuticals South Africa (pty) Ltd 27 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 31 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Canada Inc. 32 Glenmark Pharmaceuticals (Denmark Pharmaceuticals Kenya Ltd 32 Viso Farmaceuticals S.L., Spain 33 Glenmark Pharmaceuticals Nordic AB 36 Glenmark Pharmaceuticals Ecuador S.A. 38 Glenmark Pharmaceuticals Singapore Pte. Ltd. 39 Ichnos Sciences Biotherapeutics SA 40 Ichnos Sciences Inc., USA 41 Glenmark Life Sciences Limited

For and on behalf of the Board of Directors

Glenn Saldanha **Chairman & Managing Director**

Mumbai, 10 February, 2023 CORRIGENDUM: The quarterly financial results advertisement published in Financial Express, Mumbai edition on Sunday, February 12, 2023 was wrongly published by the advertising agency. The correct quarterly results had already been uploaded on the BSE, NSE and company websites. Kindly ignore the advertisement published on Sunday, February 12, 2023. The above advertisement contains the advertisement which had been approved by the Company for publication i.e. financial results for the quarter and nine months ended December 31, 2022.









